Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade

摘要: Objectives  To describe the incidence, time to onset and extent of anaemia occurring in patients with prostate cancer receiving combined hormone blockade (CHB) timing recovery from those where CHB was discontinued. Patients methods  Patients were evaluated prospectively by physical examination laboratory tests at baseline routine intervals while CHB. Of 142 who received CHB, 133 evaluable for assessment anaemia; discontinued 76 patients, whom 64 assessable their anaemia. Results  Haemoglobin levels declined significantly all a mean 149 g/L means 139 g/L, 132 g/L 131 g/L 1, 2 3 months, respectively. Haemoglobin continued decline during nadir 123 g/L 5.6 months representing absolute haemoglobin 25.4 g/L. In 120 (90%) relative ≥10% ≥25% 17 (13%) others, this subset 42.7 g/L. Significant symptoms related occurred (13%). Anaemia these easily corrected subcutaneous administration recombinant human erythropoietin. Conclusions  The associated androgen deprivation is significant occurs routinely men It normochromic, normocytic, temporally-related initiation usually resolves after discontinued. We suggest that undergo haematological testing baseline, 1–2 initiating periodically thereafter. Patients developing should be questioned about reflecting physiological compromise (e.g. angina, dyspnoea on exertion). absence other causes, suspected development treatment.